We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Breath Test Could Diagnose Colorectal Cancer

By LabMedica International staff writers
Posted on 19 Dec 2012
Print article
A simple breath analysis could be used for colorectal cancer screening, which should improve outcomes in gastrointestinal cancer patients.

Analysis of the volatile organic compounds (VOCs), which can be detected in the breath of cancer patients, is a new frontier in cancer screening as malignant tissues have different metabolism compared to normal healthy cells.

A team of scientist at the University Aldo Moro (Bari, Italy) collected exhaled breath from 37 patients with colorectal cancer and 41 healthy controls, which was processed offline to evaluate the VOC profile. The VOCs of interest had been identified and selected, and VOC patterns were able to discriminate patients from controls.

Exhaled breath was collected in a Tedlar, inert bag (Sigma-Aldrich, St Gallen, Switzerland) from patients with colorectal cancer and healthy controls who were negative at colonoscopy, and processed by thermal‐desorber gas chromatography–mass spectrometry to evaluate the VOC profile. A probabilistic neural network (PNN) validated by the leave‐one‐out method was used to identify the pattern of VOCs that better discriminated between the two groups.

Some 37 patients and 41 controls were included in the trial phase. Application of a PNN to a pattern of 15 compounds showed a discriminant performance with a sensitivity of 86%, a specificity of 83%, and an accuracy of 85% calculated as the area under the receiver operating characteristic (ROC) curve .The accuracy of PNN analysis was confirmed in the validation phase on a further 25 subjects and the model correctly assigned 19 patients, giving an overall accuracy of 76%.

Levels of some specific VOCs such as 1,3-dimethylbenzene, 1,2-pentadiene, cyclohexane, methylcyclohexane and 4-methyloctane were higher in patients with colorectal cancer than in controls. The authors concluded that the pattern of VOCs in patients with colorectal cancer was different from that in healthy controls. The PNN in this study was able to discriminate patients with colorectal cancer with an accuracy of over 75 %. Exhaled breath VOC analysis appears to have potential clinical application in colorectal cancer screening, although further studies are required to confirm its reliability in heterogeneous clinical settings.

Donato F. Altomare, MD, the senior author said, “The technique of breath sampling is very easy and noninvasive, although the method is still in the early phase of development. Our study's findings provide further support for the value of breath testing as a screening tool." The study was published on December 5, 2012, in the journal British Journal of Surgery (BJS).

Related Links:

University Aldo Moro
Sigma-Aldrich


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.